Insights Into Metastatic Castration-Resistant Prostate Cancer

Perspectives on current treatment practices regarding first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), management of progressive and/or symptomatic mCRPC

Midwest – December 2, 2020
Purchase Report

Faculty Chair

Eleni Efstathiou, MD, PhD

University of Texas MD Anderson Cancer Center, Houston, TX

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of mCRPC was held on December 2, 2020
  • Disease state and data presentations were developed in conjunction with Eleni Efstathiou, MD, PhD, from the University of Texas MD Anderson Cancer Center
  • Insights into genetic testing methods and therapies were obtained, with a particular focus on olaparib, rucaparib, genetic testing (somatic/germline); BRCA, HRR, and PALB2 mutations

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from North Dakota, Michigan, Minnesota, Illinois, and Indiana

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.